S
Susan K. Loftin
Researcher at St. Jude Children's Research Hospital
Publications - 7
Citations - 3497
Susan K. Loftin is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Immunotherapy & Cytotoxic T cell. The author has an hindex of 6, co-authored 6 publications receiving 3418 citations. Previous affiliations of Susan K. Loftin include University of Tennessee Health Science Center.
Papers
More filters
Journal ArticleDOI
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Cliona M. Rooney,Catherine Y.C. Ng,Susan K. Loftin,Colton Smith,Congfen Li,Robert A. Krance,Malcolm K. Brenner,Helen E. Heslop +7 more
TL;DR: EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation in patients with EBV reactivation after bone-marrow transplantation.
Journal ArticleDOI
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients
Cliona M. Rooney,Colton Smith,Colton Smith,Catherine Y.C. Ng,Catherine Y.C. Ng,Susan K. Loftin,Susan K. Loftin,John W. Sixbey,John W. Sixbey,Yan-jun Gan,Yan-jun Gan,Deo Kumar Srivastava,Deo Kumar Srivastava,Laura C. Bowman,Laura C. Bowman,Robert A. Krance,Robert A. Krance,Malcolm K. Brenner,Helen E. Heslop,Helen E. Heslop +19 more
TL;DR: Polyclonal donor-derived T-cell lines specific for EBV proteins can be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease.
Journal ArticleDOI
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
Helen E. Heslop,Catherine Y.C. Ng,Congfen Li,Colton Smith,Susan K. Loftin,Robert A. Krance,Robert A. Krance,Malcolm K. Brenner,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney +10 more
TL;DR: These findings support wider use of antigen–specific CTLs in adoptive immunotherapy and restore cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months.
Journal ArticleDOI
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
Cliona M. Rooney,Susan K. Loftin,Martha Holladay,Malcolm K. Brenner,Robert A. Krance,Helene E. Heslop +5 more
TL;DR: It should now be possible to use a combination of the methods described here to identify patients at high risk of developing EBV-LPD, thus enabling early therapeutic intervention.
Journal ArticleDOI
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Colton Smith,Catherine Y.C. Ng,Helen E. Heslop,Martha Holladay,Stacye Richardson,E. V. Turner,Susan K. Loftin,Congfen Li,Malcolm K. Brenner,Cliona M. Rooney +9 more
TL;DR: A method is described that allows the routine and timely preparation of large numbers of T cell-depleted bone marrow cells to allow their safe administration to bone marrow transplant recipients and how these cells may be genetically marked before infusion to determine their fate and disposition in vivo.